Skip to content

Lung Disease & Respiratory Health Center

Viagra Ingredient OK'd for Lung Problem

Revatio Cleared to Treat Pulmonary Hypertension
Font Size
A
A
A
By
WebMD Health News

June 8, 2005 -- The FDA has approved Viagra's active ingredient to treat pulmonary hypertension, a rare, life-shortening lung disorder that causes high blood pressure in the lungs.

Viagra's maker, Pfizer, a WebMD sponsor, announced the approval in a news release. Pfizer will repackage Viagra's key ingredient (sildenafil) and market it as Revatio.

Revatio would be used to improve exercise ability in patients with pulmonary hypertension, says Pfizer. The approved dose is limited to 20 milligrams three times daily. The white, round pills will look different from Viagra's blue diamonds and should be available by mid-July, says Pfizer.

Rare Condition

Pulmonary hypertension involves dangerously high pressure in the blood vessels that lead from the heart to the lungs. It affects an estimated 100,000 people worldwide, says Pfizer.

Most cases of pulmonary hypertension are due to some underlying condition, such as chronic lung or heart disease. Nearly 300 cases, mostly women in their 30s, are diagnosed per year, says the National Heart, Lung, and Blood Institute (NHLBI). There is no known cause.

Symptoms include difficulty breathing, dizziness, and fatigue. Without treatment, patients live less than three years from the time of diagnosis, on average, says Pfizer.

Another oral drug, Tracleer, is also used to treat the condition. Revatio's effectiveness hasn't been evaluated in patients taking Tracleer, says Pfizer. The drug company says Revatio is the first oral treatment approved for patients with an early stage of the progressive condition.

Study's Results

The FDA's approval was based on a study of 277 people with pulmonary hypertension, says Pfizer. Patients were randomly assigned to get a placebo or 20, 40, or 80 milligrams of Revatio three times daily.

After 12 weeks, all three Revatio groups showed "highly significant improvements" in the distance they could walk in six minutes, compared with the placebo group, says Pfizer. Average pressure in the lung arteries and other heart functions also improved with Revatio, and in a year-long trial, 94% of patients taking Revatio were still alive, says Pfizer.

No particular dose had an advantage, and the lowest dose was approved.

Today on WebMD

man coughing
You may not even know you have it.
blood clot
Signs of this potentially fatal complication.
 
man coughing
When a cold becomes bronchitis.
human lungs
Causes behind painful breathing, fluid buildup.
 

chest x-ray
Slideshow
Bronchitis Overview
SLIDESHOW
 
Copd Myth Fact Quiz
QUIZ
Energy Boosting Foods
SLIDESHOW
 

Pollen counts, treatment tips, and more.

It's nothing to sneeze at.

Loading ...

Sending your email...

This feature is temporarily unavailable. Please try again later.

Thanks!

Now check your email account on your mobile phone to download your new app.

lungs
Article
smokestacks
Article
 
woman coughing
Article
Lung xray and caduceus
Article
 

WebMD Special Sections